Ibuprofene eg orange - fever and pain treatment 150 ml

Product Description

Symptomatic treatment of fever and mild to moderate pain.

Indications

Ibuprofen Eg syrup for children is useful in the treatment of fever and pain.

Composition

Active ingredients

Each ml of oral suspension contains: Active ingredient: ibuprofen 20 mg.

Excipients

Orange 100mg/5ml sugar-free orange-flavored oral suspension Citric acid monohydrate, sodium citrate, acesulfame potassium, xanthan gum, sodium benzoate, orange flavoring, maltitol syrup, glycerin, purified water.

Directions for use and Dosage

The daily dose is structured according to the weight and age of the patient.
Undesirable effects may be minimized by using the lowest effective dose for the shortest duration of treatment necessary to control symptoms.
In children aged between 3 and 6 months, limit administration to those weighing more than 5.6 kg.
Oral administration to infants and children aged between 3 months and 12 years should be done using the dosing syringe supplied with the product.
The graduated scale on the body of the syringe clearly shows the notches for the different dosages; in particular, the 2.5 ml mark corresponding to 50 mg of ibuprofen and the 5 ml mark corresponding to 100 mg of ibuprofen.
The daily dose of 20–30 mg/kg of body weight, divided 3 times a day at intervals of 6–8 hours, can be used to control the symptoms. be administered according to the following scheme.

Warnings

There is a risk of impaired renal function in dehydrated children and adolescents.
The use of ibuprofen, acetylsalicylic acid or other analgesics, antipyretics, nonsteroidal anti-inflammatory drugs requires particular caution:

• in case of asthma: possible bronchoconstriction;
• in the presence of coagulation defects: reduced coagulability;
• in the presence of renal, cardiac or hypertension diseases: possible critical reduction of renal function (especially in subjects with impaired renal or hepatic function, heart failure or under treatment with diuretics), nephrotoxicity or fluid retention;
• in the presence of liver diseases: possible hepatotoxicity.
• rehydrate the subject before the start and during treatment in case of dehydration (for example due to fever, vomiting or diarrhea);

Interactions

The following interactions are common to ibuprofen, acetylsalicylic acid and other analgesics, antipyretics, non-steroidal anti-inflammatory drugs (NSAIDs):

• avoid the simultaneous use of two or more analgesics, antipyretics, non-steroidal anti-inflammatory drugs: increased risk of adverse effects
• corticosteroids: increased risk of gastrointestinal ulceration or bleeding
• antibacterials: possible increased risk of quinolone-induced convulsions
• anticoagulants: NSAIDs may increase the effects of anticoagulants, such as warfarin (see section 4.4)
• antiplatelet agents and selective serotonin reuptake inhibitors (SSRIs): increased risk of gastrointestinal bleeding
• antidiabetics: possible increased effect of sulfonylureas
• antivirals: ritonavir, possible increase in the concentration of NSAIDs
• ciclosporin: increased risk of nephrotoxicity
• cytotoxics: methotrexate, decreased excretion (increased risk of toxicity)
• lithium: reduced excretion (increased risk of toxicity)
• tacrolimus: increased risk of nephrotoxicity
• uricosurics: probenecid, slows the excretion of NSAIDs (increase in plasma concentrations)
• methotrexate: potential increase in plasma concentrations of methotrexate.
• Zidovudine: increased risk of haemarthrosis and haematomas in HIV (+) haemophiliacs if treated concomitantly with zidovudine and ibuprofen.
• diuretics, ACE inhibitors and Angiotensin II antagonists: NSAIDs may reduce the effect of diuretics and other antihypertensive drugs. In some patients with compromised renal function (e.g., dehydrated patients or elderly patients with compromised renal function), the co-administration of an ACE inhibitor or an angiotensin II antagonist and agents that inhibit the cyclooxygenase system may lead to further deterioration of renal function, including possible acute renal failure, which is usually reversible.

Pregnancy and breastfeeding

Persons under 12 years of age are unlikely to become pregnant or breastfeed. However, in such circumstances, the following considerations should be taken into account.
Inhibition of prostaglandin synthesis may adversely affect pregnancy and/or embryo/foetal development.
Results of epidemiological studies suggest an increased risk of miscarriage and cardiac malformation and gastroschisis after use of a prostaglandin synthesis inhibitor in early pregnancy.
The absolute risk of cardiac malformations increased from less than 1% to approximately 1.5%.
The risk is believed to increase with dose and duration of therapy.

Storage

No special requirements.

Format

150 ml bottle.